EUCTR2006-000854-32-AT进行中（未招募）不适用
Rituximab in Rheumatoid Arthritis in Patients Who Failed Therapy With TNF-Blockers
Vienna Medical University0 个研究点目标入组 20 人开始时间: 2006年5月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion criteria
- •-Women or men 18 years of age or older
- •-Diagnosis of RA according to the revised 1987 criteria of the ARA (5) for at least 3 months prior to first administration of study medication
- •-The current treatment with Etanercept, Infliximab or Adalimumab in combination with MTX is insufficient. The patient’s disease is considered to be active despite DMARD treatment.
- •-Active disease at the time of screening as defined by:
- •o= 6 swollen on a 66/68 joint count
- •o= 6 tender joints on a 66/68 joint count
- •oand one out of the following 3 categories
- •?ESR = 28 mm/ h
- •?CRP = 1.5 mg/ dl
- •?Morning stiffness = 45 min
- •oAnd one out of the following 3 categories
- •?Bone erosion by x-ray prior to first administration of study medication
- •?Anti-cyclic citrullinated peptide (Anti-CCP) antibody-positive
- •?Rheumatoid factor (RF)-positive at screening
- •-If using NSAIDs or other analgesics for RA, must be on a stable dose for at least 2 weeks prior to the first administration of study agent.
- •-If using oral corticosteroids, must be on a stable dose equivalent to = 10 mg of prednisone/day for at least 2 weeks prior to first administration of study agent. If currently not using corticosteroids, the subject must not have received oral corticosteroids for at least 2 weeks prior to first administration of study medication.
- •-Women of childbearing potential or men capable of fathering children must be using adequate birth control measures (eg, abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, surgical sterilization) during the study and for 6 months after receiving the last administration of study agent.
- •-Female subjects of childbearing potential must test negative for pregnancy.
- •-The screening laboratory test must meet the following criteria:
- •oHemoglobin = 8.5 g/ dl providing the low hemoglobin level is not due to other diseases than anemia of chronic inflammation.
- •oWBC = 3500 / µl
- •oNeutrophils = 1500 / µl
- •oPlatelets = 100 000 / µl
- •oSerum transaminase = 2 times the upper limit of normal
- •oSerum creatinine = 1.7 mg/ dl
- •-The patient must be able to adhere the study visit schedule and other protocol requirements and must have given informed consent prior to any screening procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria
- •Patients are excluded if they meet one of the following criteria:
- •-Pregnant women, nursing mothers or a planned pregnancy within six months after last scheduled treatment
- •-Patients with other inflammatory diseases that might interfere with the evaluation of the psoriatic arthritis.
- •-Patients with fibromyalgia syndrome
- •-Use of IM, IV, IA cortocisteroids within 4 weeks prior to screening.
- •-Treatment with any investigational drug within 3 months prior to screening.
- •-A history of known allergy to murine proteins, e.g. allergy to Infliximab
- •-History of infected joint prothesis within the previous 5 years
- •-Chronic infections
- •-History of active tuberculosis requiring treatment within the previous 3 years, or history of opportunistic infections within 2 months, uncontrolled active infection or documented HIV infection. Also excluded are patients with evidence of latent tuberculosis and patients with old tuberculosis without documented adequate therapy if they will not be treated according to the local TB guidelines.
- •-Current signs or symptoms of other severe uncontrolled disease which in the investigators opinion would put the patient at an unacceptable risk
- •-History of lymphoproliferative disease, any current malignancies or history of malignancy within 5 years other than successfully treated basal cell carcinoma or squamous cell carcinoma of the skin
- •-History of drug abuse
- •->75 years
研究者
相似试验
已完成
不适用
Rituximab in Rheumatoid Arthritis in patients who failed therapy with tumour necrosis factor-blockers: a multi-centre clinical observational real-life study (phase IIIb)Rheumatoid Arthritis (RA)Musculoskeletal DiseasesISRCTN27093749Medical University of Vienna (Austria)20
进行中（未招募）
不适用
Re-Treatment with Rituximab in patients with rheumatoid arthritis who have had an inadequate response to not more than one aTNF (extension study to ML19070) - Efficacy of re-therapy in anti-TNFalpha IRMedDRA version: 9.1Level: PTClassification code 10039073Term: Rheumatoid arthritisRheumatoid arthritisEUCTR2006-006746-33-DERoche Pharma AG240
招募中
2 期
Safety and Efficacy of Rituximab in patients with juvenile dermatomyositisJuvenile dermatomyositisJuvenile dermatomyositis.M33.0IRCT20231119060108N1Shahid Beheshti University of Medical Sciences7
进行中（未招募）
不适用
Efficacy of Rituximab treatment in patients with rheumatoid arthritis having inadequate response to TNF blockerTo investigate the efficacy of treatment with Rituximab (MabThera®) in patients with active RA whose current treatment with one or more TNF-blocker (Etanercept - Enbrel®, Infliximab – Remicade® or Adalimumab - Humira®) alone or in combination with MTX is insufficient measured by DAS28 activity index.EUCTR2006-004673-98-HURoche (Hungary) Ltd.20
进行中（未招募）
不适用
Efficacy and safety of rituximab in patients with rheumatoid arthritis - FIRSTMedDRA version: 8.1Level: PTClassification code 10039073Term: Rheumatoid arthritisRheumatoid arthritisEUCTR2006-001000-37-DERoche Pharma AG300